Overexpressed Gal-3 in the brain and CSF may alter amyloid plaque aggregation and increase plaque-associated toxicity in AD patients (Cai et al., 2014; Ozben and Ozben, 2019; Tan et al., 2021). The gene discussed is LGALS3; the disease is Alzheimer disease.